The phase II GETNE-DUTHY trial reports on durvalumab plus tremelimumab in advanced thyroid carcinoma. The study evaluates the checkpoint inhibitor combination approach led by Capdevila and colleagues and provides early clinical data for a patient population with limited durable options. Checkpoint strategies are increasingly explored across rare and difficult-to-treat tumors, but thyroid cancer remains a distinct disease setting where response rates and toxicity profiles vary by histology and prior therapy. The key industry takeaway from the trial report is the continued push to establish immunotherapy combinations with measurable activity signals, potentially informing subsequent study designs and biomarker hypotheses in advanced thyroid cancer.